文摘
目的:描述了渐进多焦点的脑白质病(PML)和免疫重建炎性综合症(IRIS)课程,治疗和结果。设计方法:临床和neuroradiological 34 MS患者的数据体现natalizumab-related PML从2009年11月到2015年5月获得25意大利多发性硬化症(MS)中心和分析在当前工作。结果:PML残疾峰观察到6月(平均eds增加1.2分相比PML开始),证实了18个月后跟进(意味着eds从基线增加0.7分)。更多的CSF病毒复制是糟糕的临床相关课程或死亡。29个病人幸存下来,3例死于6个月内的PML发作,2例死亡3年内由于长期床上不动。降低磁共振成像病变扩大,单聚焦的演讲是一个更好的临床演变,除非subtentorial病变。19/34的患者表现出虹膜和亚急性临床恶化后的头5个月,PML发病;15人用静脉注射类固醇治疗的临床改善。10/34患者癫痫发作观察(29.5 [percnt]), 2人在PML发作,PML复苏后5在虹膜和3。2与广义tonic-clonic发作患者呈现,1与癫痫持续状态和7焦攻击。 Drugs showed poor efficacy during the acute phase of epilepsia, however their efficacy improved over time. Conclusions: Most of patients survived to PML but manifested a slight long term worsening of their clinical condition. Steroid treatment of IRIS might reverse the IRIS-related disability increment. Epileptic seizures were commonly observed in PML and a progressive improvement of pharmacological response can be expected during the follow-up.
披露:德罗西博士没有披露。Cordioli博士已经收到个人补偿活动和Genzyme生原体Idec。阿马托博士已经收到个人活动与补偿Idec,默克Serono、拜耳、诺华、Teva,赛诺菲,Genzyme Almirall。阿马托博士已经收到个人活动与补偿Idec,默克Serono、拜耳、诺华、Teva,赛诺菲,Genzyme Almirall。Clerico博士已经收到个人活动与默克公司Serono补偿作为一个顾问委员会成员。Deotto博士已经与诺华收到个人补偿活动,TEVA, Almirall De Riz博士已经收到个人赔偿的活动与默克Serono担任顾问。Scarpazza博士没有披露。褐博士没有披露。Ghezzi博士已经收到个人活动与补偿Idec, Merk-Serono,诺华公司Genzyme Teva, Serono座谈会Int发现。诺华,Almirall。格里马尔迪博士已经收到资助旅行或演讲者从默克公司Serono谢礼,Idec,赛诺菲-安万特,诺华和梯瓦制药产业公司。格里马尔迪博士已经收到资助旅行或演讲者从默克公司Serono谢礼,Idec,赛诺菲-安万特,诺华和梯瓦制药产业公司Lugaresi博士已经收到个人赔偿activtiies拜耳医疗、Idec, Genzyme /赛诺菲,EMD Serono,诺华,和梯瓦中枢神经系统。 Dr. Lugaresi has received research support from Bayer Healthcare and Biogen. Dr. Moiola has received personal compensation for activities with Biogen Idec, Genzyme-Sanofi, Novartis and Merck Serono as a speaker, Dr. Perrone has received personal compensation for activities with Biogen Idec, Merk-Serono, Teva Neurosceince, Novartis, and Genzyme Corporation. Dr. Prosperini has received personal compensation for activities with Bayer Schering, Biogen Idec, Genzyme, Novartis, and Teva Neuroscience. Dr. Rezzonico has received personal compensation for activities with Biogen Idec, Merck Serono, Bayer, Teva, Novartis, Sanofi-Aventis, and Baxter. Dr. Rovaris has received personal compensation for activities with Almirall, Biogen, Genzyme-Sanofi, and Teva. Dr. Salemi has received research support from Merck Serono, Biogen-Idec, Teva Neuroscience, Novartis, Bayer Pharmaceuticals Corporation, and Sanofi-Aventis Pharmaceuticals. Dr. Salvetti has received personal compensation for activities with Sanofi-Aventis, Biogen Idec, Bayer Schering, and Merck Serono. Dr. Salvetti has received research support from the Italian Multiple Sclerosis Foundation (FISM). Dr. Santuccio has received personal compensation from Novartis and Teva for activities as a speaker. Dr. Tortorella has received personal compensation for activities with Biogen, Sanofi-Aventis, Serono and Bayer-Schering, Teva,Genzyme and Novartis as a speaker. Dr. Ruggero Capra has nothing to disclose.
星期日,2016年4月17日,8:30 am-5:30点
- 版权©2016年长企业公司,。
